118 related articles for article (PubMed ID: 9854494)
1. p53 expression affects the efficacy of adjuvant chemotherapy after resection of invasive ductal carcinoma of the pancreas.
Nio Y; Dong M; Uegaki K; Hirahara N; Minari Y; Sasaki S; Takamura M; Iguchi C; Tamura K
Anticancer Res; 1998; 18(5B):3773-9. PubMed ID: 9854494
[TBL] [Abstract][Full Text] [Related]
2. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
[TBL] [Abstract][Full Text] [Related]
3. Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas.
Nio Y; Dong M; Uegaki K; Hirahara N; Minari Y; Sasaki S; Takamura M; Iguchi C; Tamura K
Pancreas; 1999 Mar; 18(2):117-26. PubMed ID: 10090408
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
[TBL] [Abstract][Full Text] [Related]
5. Expression of retinoblastoma and p53 pathway-related proteins in resectable invasive ductal carcinoma of the pancreas: potential cooperative effects on clinical outcome.
Hashimoto K; Nio Y; Koike M; Itakura M; Yano S; Higami T; Maruyama R
Anticancer Res; 2005; 25(2B):1361-8. PubMed ID: 15865092
[TBL] [Abstract][Full Text] [Related]
6. p53 protein expression as prognostic factor in human pancreatic cancer.
Sato Y; Nio Y; Song MM; Sumi S; Hirahara N; Minari Y; Tamura K
Anticancer Res; 1997; 17(4A):2779-88. PubMed ID: 9252715
[TBL] [Abstract][Full Text] [Related]
7. p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer.
Ahrendt SA; Brown HM; Komorowski RA; Zhu YR; Wilson SD; Erickson BA; Ritch PS; Pitt HA; Demeure MJ
Surgery; 2000 Oct; 128(4):520-30. PubMed ID: 11015084
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive ductal carcinoma of the pancreas.
Nio Y; Omori H; Hashimoto K; Itakura M; Koike M; Yano S; Toga T; Higami T; Maruyama R
Anticancer Res; 2005; 25(5):3523-9. PubMed ID: 16101174
[TBL] [Abstract][Full Text] [Related]
9. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
11. The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome.
Toga T; Nio Y; Hashimoto K; Higami T; Maruyama R
Anticancer Res; 2004; 24(2C):1173-8. PubMed ID: 15154643
[TBL] [Abstract][Full Text] [Related]
12. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
13. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy.
Nio Y; Dong M; Iguchi C; Yamasawa K; Toga T; Itakura M; Tamura K
J Surg Oncol; 2001 Mar; 76(3):188-96. PubMed ID: 11276023
[TBL] [Abstract][Full Text] [Related]
14. Expression of Gadd45a and p53 proteins in human pancreatic cancer: potential effects on clinical outcomes.
Dong M; Dong Q; Zhang H; Zhou J; Tian Y; Dong Y
J Surg Oncol; 2007 Mar; 95(4):332-6. PubMed ID: 17230496
[TBL] [Abstract][Full Text] [Related]
15. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
16. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
Miller RC; Iott MJ; Corsini MM
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):364-8. PubMed ID: 19735864
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas.
Jinfeng M; Kimura W; Sakurai F; Moriya T; Mizutani M; Hirai I
Hepatogastroenterology; 2007 Sep; 54(78):1635-40. PubMed ID: 18019682
[TBL] [Abstract][Full Text] [Related]
18. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
19. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.
Casneuf VF; Fonteyne P; Van Damme N; Demetter P; Pauwels P; de Hemptinne B; De Vos M; Van de Wiele C; Peeters M
Cancer Invest; 2008 Oct; 26(8):852-9. PubMed ID: 18853313
[TBL] [Abstract][Full Text] [Related]
20. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
